Advertisement

Journal of Neurology

, Volume 266, Issue 6, pp 1340–1350 | Cite as

Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease

  • Tatiana Aldaz
  • Pasquale Nigro
  • Almudena Sánchez-Gómez
  • Celia Painous
  • Lluís Planellas
  • Pilar Santacruz
  • Ana Cámara
  • Yaroslau Compta
  • Francesc Valldeoriola
  • Maria J. Martí
  • Esteban MuñozEmail author
Original Communication

Abstract

Background/aims

The presence of non-motor symptoms in Huntington’s disease (HD) has not been systematically assessed so far. Our objective was to know their prevalence and to compare it with a cohort of patients with Parkinson’s disease (PD).

Materials and methods

Participants were consecutively recruited from our outpatient clinic. They were assessed through the motor part of the Unified Huntington’s Disease Rating Scale, the motor part of the Unified Parkinson’s Disease Rating Scale, the total functional capacity scale and the PD non-motor symptoms questionnaire.

Results

We enrolled 123 participants: 53 HD, 45 PD and 25 healthy controls (HC). Non-motor symptoms were significantly more prevalent in HD patients than in HC. The most frequent non-motor symptoms in HD, involving more than 50% of patients, were attentional deficits, apathy, dysphagia, memory complaints, depression falls, insomnia and urinary urgency. The total score of non-motor symptoms correlated with disease duration, total functional capacity and disease stage. HD scored significantly higher than PD in 11 items (dysphagia, constipation, bowel incontinence, faecal tenesmus, weight loss, memory, apathy, attention, falls, nightmares, delusions) and in four domains (cognitive, hallucinations and delusions, digestive and cardiovascular). PD did not score significantly higher than HD in any domain.

Conclusions

HD patients have a high prevalence of non-motor symptoms, which is even higher than in PD, and correlates with disease progression.

Keywords

Huntington’s disease Parkinson’s disease Non-motor symptoms PD NMSQuest 

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical standards

The authors state that this study has been approved by the ethic committee of Hospital Clinic of Barcelona and have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

References

  1. 1.
    Bates GP (2005) The molecular genetics of Huntington disease—a history. Nat Rev Genet 6:766–773CrossRefGoogle Scholar
  2. 2.
    Walker FO (2007) Huntington’s disease. Lancet 369:218–228CrossRefGoogle Scholar
  3. 3.
    Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227:770–773CrossRefGoogle Scholar
  4. 4.
    Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW (2016) Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol 26:726–740CrossRefGoogle Scholar
  5. 5.
    Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731CrossRefGoogle Scholar
  6. 6.
    Mielcarek M (2015) Huntington’s disease is a multi-system disorder. Rare Dis 3:e1058464CrossRefGoogle Scholar
  7. 7.
    Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD (2018) Electrocardiogram abnormalities suggest aberrant cardiac conduction in Huntington’s disease. Mov Disord Clin Pract 5:306–311CrossRefGoogle Scholar
  8. 8.
    Van der Burg JMM, Winqvist A, Aziz NA, Maat-Schieman MLC, Roos RAC, Bates GP, Brundin P, Björkqvist M, Wierup N (2011) Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis 44:1–8CrossRefGoogle Scholar
  9. 9.
    Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ (2015) Treating the whole body in Huntington’s disease. Lancet Neurol 14:1135–1142CrossRefGoogle Scholar
  10. 10.
    Stuwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, Saft C (2013) Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 80:743–746CrossRefGoogle Scholar
  11. 11.
    Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AHV, Brown RG, Antonini A, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P (2015) The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Park Relat Disord 21:287–291CrossRefGoogle Scholar
  12. 12.
    Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923CrossRefGoogle Scholar
  13. 13.
    Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11:136–142CrossRefGoogle Scholar
  14. 14.
    Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefGoogle Scholar
  15. 15.
    Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Agarwal P, Athar S, Bordelan Y, Bronte-Stewart HM, Camicioli R, Chou K, Cole W, Dalvi A, Delgado H, Diamond A, Dick JP, Duda J, Elble RJ, Evans C, Evidente VG, Fernandez HH, Fox S, Friedman JH, Fross RD, Gallagher D, Goetz CG, Hall D, Hermanowicz N, Hinson V, Horn S, Hurtig H, Kang UJ, Kleiner-Fisman G, Klepitskaya O, Kompoliti K, Lai EC, Leehey ML, Leroi I, Lyons KE, McClain T, Metzer SW, Miyasaki J, Morgan JC, Nance M, Nemeth J, Pahwa R, Parashos SA, Schneider JSJS, Schrag A, Sethi K, Shulman LM, Siderowf A, Silverdale M, Simuni T, Stacy M, Stern MB, Stewart RM, Sullivan K, Swope DM, Wadia PM, Walker RW, Walker R, Weiner WJ, Wiener J, Wilkinson J, Wojcieszek JM, Wolfrath S, Wooten F, Wu A, Zesiewicz TA, Zweig RM (2008) Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170.  https://doi.org/10.1002/mds.22340 CrossRefGoogle Scholar
  16. 16.
    Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–1CrossRefGoogle Scholar
  17. 17.
    Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649CrossRefGoogle Scholar
  18. 18.
    Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629CrossRefGoogle Scholar
  19. 19.
    Sauerbier A, Chaudhuri KR (2014) Non-motor symptoms: the core of multi-morbid Parkinson’s disease. Br J Hosp Med 75:18–24CrossRefGoogle Scholar
  20. 20.
    Aziz NA, Swaab DF, Pijl H, Roos RAC (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s Disease: clinical consequences and therapeutic implications. Rev Neurosci 18:223–252CrossRefGoogle Scholar
  21. 21.
    Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):14–20CrossRefGoogle Scholar
  22. 22.
    Heemskerk A-W, Roos RAC (2012) Aspiration pneumonia and death in Huntington’s disease. PLoS Curr 4:RRN1293CrossRefGoogle Scholar
  23. 23.
    Heemskerk A-W, Roos RAC (2011) Dysphagia in Huntington’s disease: a review. Dysphagia 26:62–66CrossRefGoogle Scholar
  24. 24.
    Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14:625–639CrossRefGoogle Scholar
  25. 25.
    Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One 4:e8025CrossRefGoogle Scholar
  26. 26.
    Ondo WG, Tintner R, Thomas M, Jankovic J (2002) Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol 25:300–302CrossRefGoogle Scholar
  27. 27.
    De Hert M, Dockx L, Bernagie C, Peuskens B, Sweers K, Leucht S, Tack J, Van de Straete S, Wampers M, Peuskens J (2011) Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol 11:17CrossRefGoogle Scholar
  28. 28.
    Stocchi F, Torti M (2017) Constipation in Parkinson’s disease. Int Rev Neurobiol 134:811–826CrossRefGoogle Scholar
  29. 29.
    Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm 125:1237–1250CrossRefGoogle Scholar
  30. 30.
    Nordin S, Paulsen JS, Murphy C (1995) Sensory- and memory-mediated olfactory dysfunction in Huntington’s disease. J Int Neuropsychol Soc 1:281–290CrossRefGoogle Scholar
  31. 31.
    Barrios FA, Gonzalez L, Favila R, Alonso ME, Salgado PM, Diaz R, Fernandez-Ruiz J (2007) Olfaction and neurodegeneration in HD. Neuroreport 18:73–76CrossRefGoogle Scholar
  32. 32.
    Kandasamy M, Rosskopf M, Wagner K, Klein B, Couillard-Despres S, Reitsamer HA, Stephan M, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Horsten S, Aigner L (2015) Reduction in subventricular zone-derived olfactory bulb neurogenesis in a rat model of Huntington’s disease is accompanied by striatal invasion of neuroblasts. PLoS One 10:e0116069CrossRefGoogle Scholar
  33. 33.
    Aziz NA, Anguelova GV, Marinus J, Van Dijk JG, Roos RAC (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur J Neurol 17:1068–1074CrossRefGoogle Scholar
  34. 34.
    Kolenc M, Moharic M, Kobal J, Podnar S (2014) Bladder dysfunction in presymptomatic gene carriers and patients with Huntington’s disease. J Neurol 261:2360–2369CrossRefGoogle Scholar
  35. 35.
    Rana AQ, Vaid H, Akhter MR, Awan NY, Fattah A, Cader MH, Hafez K, Rana MA, Yousuf MS (2014) Prevalence of nocturia in Parkinson’s disease patients from various ethnicities. Neurol Res 36:234–238CrossRefGoogle Scholar
  36. 36.
    Vaughan CP, Bliwise DL (2018) Sleep and nocturia in older adults. Sleep Med Clin 13:107–116CrossRefGoogle Scholar
  37. 37.
    Dumas EM, van den Bogaard SJA, Middelkoop HAM, Roos RAC (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18CrossRefGoogle Scholar
  38. 38.
    Montoya A, Pelletier M, Menear M, Duplessis E (2006) Episodic memory impairment in Huntington’ s disease: a meta-analysis. Neuropsychologia 44:1984–1994CrossRefGoogle Scholar
  39. 39.
    Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB (2010) Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. PLoS Curr 2:RRN1184Google Scholar
  40. 40.
    Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R (2012) A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 29:639–658Google Scholar
  41. 41.
    Naarding P, Janzing JGE, Eling P, van der Werf S, Kremer B (2009) Apathy is not depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 21:266–270CrossRefGoogle Scholar
  42. 42.
    Reedeker N, Bouwens JA, van Duijn E, Giltay EJ, Roos RAC, van der Mast RC (2011) Incidence, course, and predictors of apathy in Huntington’s disease: a two-year prospective study. J Neuropsychiatry Clin Neurosci 23:434–441CrossRefGoogle Scholar
  43. 43.
    van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RAC, van der Mast RC (2014) Course of irritability, depression and apathy in Huntington’s disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 13:9–16Google Scholar
  44. 44.
    van Duijn E, Reedeker N, Giltay EJ, Roos RAC, van der Mast RC (2010) Correlates of apathy in Huntington’s disease. J Neuropsychiatry Clin Neurosci 22:287–294CrossRefGoogle Scholar
  45. 45.
    Martinez-Horta S, Perez-Perez J, Sampedro F, Pagonabarraga J, Horta-Barba A, Carceller-Sindreu M, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernandez-Leon A, Carrio I, Kulisevsky J (2018) Structural and metabolic brain correlates of apathy in Huntington’s disease. Mov Disord 33(7):1151–1159CrossRefGoogle Scholar
  46. 46.
    Sousa M, Moreira F, Jesus-Ribeiro J, Marques I, Cunha F, Canário N, Freire A, Januário C (2018) Apathy profile in Parkinson’s and Huntington’s disease: a comparative cross-sectional study. Eur Neurol 79:13–20CrossRefGoogle Scholar
  47. 47.
    Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24:2391–2397CrossRefGoogle Scholar
  48. 48.
    Krishnamoorthy A, Craufurd D (2011) Treatment of apathy in Huntington’s disease and other movement disorders. Curr Treat Options Neurol 13:508–519CrossRefGoogle Scholar
  49. 49.
    Ory-Magne F, Corvol J-C, Azulay J-P, Bonnet A-M, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300–307CrossRefGoogle Scholar
  50. 50.
    van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441–448CrossRefGoogle Scholar
  51. 51.
    Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, Zugno E, Caletti E (2017) Neuropsychiatric burden in Huntington’s disease. Brain Sci 7:67CrossRefGoogle Scholar
  52. 52.
    Thompson JC, Snowden JS, Craufurd D, Neary D (2002) Behavior in Huntington’s disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 14:37–43CrossRefGoogle Scholar
  53. 53.
    Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17:496–502CrossRefGoogle Scholar
  54. 54.
    Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162:725–731CrossRefGoogle Scholar
  55. 55.
    Hubers AAM, van Duijn E, Roos RAC, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ (2013) Suicidal ideation in a European Huntington’s disease population. J Affect Disord 151:248–258CrossRefGoogle Scholar
  56. 56.
    Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW (2018) NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl Psychiatry 8:117CrossRefGoogle Scholar
  57. 57.
    Mendez MF (1994) Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 24:189–208CrossRefGoogle Scholar
  58. 58.
    van Duijn E, Craufurd D, Hubers AAM, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB (2014) Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85:1411–1418CrossRefGoogle Scholar
  59. 59.
    Register SL, Ruano OL, Sanchez DL, Catalano G, Catalano MC (2017) Hallucinations associated with topiramate therapy: a case report and review of the literature. Curr Drug Saf 12:193–197CrossRefGoogle Scholar
  60. 60.
    Nakamura M, Koo J (2016) Drug-induced tactile hallucinations beyond recreational drugs. Am J Clin Dermatol 17:643–652CrossRefGoogle Scholar
  61. 61.
    Diederen KMJ, Neggers SFW, de Weijer AD, van Lutterveld R, Daalman K, Eickhoff SB, Clos M, Kahn RS, Sommer IEC (2013) Aberrant resting-state connectivity in non-psychotic individuals with auditory hallucinations. Psychol Med 43:1685–1696CrossRefGoogle Scholar
  62. 62.
    Dewhurst K, Oliver JE, McKnight AL (1970) Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 116:255–258CrossRefGoogle Scholar
  63. 63.
    Fedoroff JP, Peyser C, Franz ML, Folstein SE (1994) Sexual disorders in Huntington’s disease. J Neuropsychiatry Clin Neurosci 6:147–153CrossRefGoogle Scholar
  64. 64.
    Reininghaus E, Lackner N (2015) Relationship satisfaction and sexuality in Huntington’s disease. Handb Clin Neurol 130:325–334CrossRefGoogle Scholar
  65. 65.
    Kolenc M, Kobal J, Podnar S (2017) Female sexual dysfunction in presymptomatic mutation carriers and patients with Huntington’s disease. J Huntingtons Dis 6:105–113CrossRefGoogle Scholar
  66. 66.
    Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56:1248–1252CrossRefGoogle Scholar
  67. 67.
    van der Burg JMM, Björkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 8:765–774CrossRefGoogle Scholar
  68. 68.
    Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M (2008) Falls and gait disturbances in Huntington’s disease. Mov Disord 23:970–976CrossRefGoogle Scholar
  69. 69.
    Verhaeverbeke I, Mets T (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17:105–118CrossRefGoogle Scholar
  70. 70.
    Hansotia P, Wall R, Berendes J (1985) Sleep disturbances and severity of Huntington’s disease. Neurology 35:1672–1674CrossRefGoogle Scholar
  71. 71.
    Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A (2008) Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 65:482–488CrossRefGoogle Scholar
  72. 72.
    Silvestri R, Raffaele M, De Domenico P, Tisano A, Mento G, Casella C, Tripoli MC, Serra S, Di Perri R (1995) Sleep features in Tourette’s syndrome, neuroacanthocytosis and Huntington’s chorea. Neurophysiol Clin Neurophysiol 25:66–77CrossRefGoogle Scholar
  73. 73.
    Varda E, Demetriou CA, Heraclides A, Christou YP, Zamba-Papanicolaou E (2016) Quality of life of Cypriot patients suffering with Huntington’s disease. PLoS Curr 8:ecurrentsGoogle Scholar
  74. 74.
    Johnson MO, Frank S, Mendlik M, Casarett D (2018) Utilization of hospice services in a population of patients with Huntington’s disease. J Pain Symptom Manage 55:440–443CrossRefGoogle Scholar
  75. 75.
    Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11:542–548CrossRefGoogle Scholar
  76. 76.
    Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED (1991) Factors associated with slow progression in Huntington’s disease. Arch Neurol 48:800–804CrossRefGoogle Scholar
  77. 77.
    Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J Endocrinol 151:451–455CrossRefGoogle Scholar
  78. 78.
    Aziz NA, van der Burg JMM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RAC (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71:1506–1513CrossRefGoogle Scholar
  79. 79.
    Mahant N, McCusker EA, Byth K, Graham S (2003) Huntington’s disease: clinical correlates of disability and progression. Neurology 61:1085–1092CrossRefGoogle Scholar
  80. 80.
    Goodman AOG, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA (2008) The metabolic profile of early Huntington’s disease—a combined human and transgenic mouse study. Exp Neurol 210:691–698CrossRefGoogle Scholar
  81. 81.
    Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay J-P, Tranchant C, Broussolle E, Morin F, Bachoud-Levi A-C, Maison P (2009) Neuroendocrine disturbances in Huntington’s disease. PLoS One 4:e4962CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Tatiana Aldaz
    • 1
  • Pasquale Nigro
    • 1
  • Almudena Sánchez-Gómez
    • 1
  • Celia Painous
    • 1
  • Lluís Planellas
    • 1
  • Pilar Santacruz
    • 1
    • 4
  • Ana Cámara
    • 1
  • Yaroslau Compta
    • 1
    • 2
    • 3
  • Francesc Valldeoriola
    • 1
    • 2
    • 3
  • Maria J. Martí
    • 1
    • 2
    • 3
  • Esteban Muñoz
    • 1
    • 2
    • 3
    • 4
    Email author
  1. 1.Parkinson’s Disease and Movement Disorders Unit, Department of NeurologyHospital Clinic of BarcelonaBarcelonaSpain
  2. 2.Institut de NeurociènciesUniversity of BarcelonaBarcelonaSpain
  3. 3.Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
  4. 4.European Huntington’s Disease Network (EHDN)BarcelonaSpain

Personalised recommendations